CO2019011569A2 - Método para preparar una composición con un bajo contenido de oxígeno disuelto, que comprende paracetamol, y opcionalmente uno o más aine, y una composición obtenida de la misma - Google Patents
Método para preparar una composición con un bajo contenido de oxígeno disuelto, que comprende paracetamol, y opcionalmente uno o más aine, y una composición obtenida de la mismaInfo
- Publication number
- CO2019011569A2 CO2019011569A2 CONC2019/0011569A CO2019011569A CO2019011569A2 CO 2019011569 A2 CO2019011569 A2 CO 2019011569A2 CO 2019011569 A CO2019011569 A CO 2019011569A CO 2019011569 A2 CO2019011569 A2 CO 2019011569A2
- Authority
- CO
- Colombia
- Prior art keywords
- paracetamol
- composition
- nsaids
- optionally
- container
- Prior art date
Links
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 title abstract 4
- 229960005489 paracetamol Drugs 0.000 title abstract 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 229910052760 oxygen Inorganic materials 0.000 title abstract 3
- 239000001301 oxygen Substances 0.000 title abstract 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 title 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 3
- 239000008215 water for injection Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000010438 heat treatment Methods 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención proporciona un método para preparar una composición acuosa para administración intravenosa que comprende paracetamol, y opcionalmente uno o más fármacos antiinflamatorios no esteroides (AINE), por lo cual el oxígeno disuelto de la composición en un recipiente cerrado es de 1,0 ppm como máximo, caracterizado dicho método porque comprende enjuagar por lo menos una vez un recipiente para la producción del compuesto con agua de una temperatura de por lo menos 80°C, calentando de este modo el recipiente y creando un entorno de bajo contenido de oxígeno en dicho recipiente; y en dicho recipiente enjuagado disolver paracetamol en agua par inyectables, donde dicha agua para inyectables está a una temperatura de por lo menos 80°C, por medio de lo cual opcionalmente uno o más AINE se agregan antes de o después de disolver el paracetamol.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2017/059440 WO2018192664A1 (en) | 2017-04-20 | 2017-04-20 | METHOD FOR PREPARING A COMPOSITION WITH A LOW DISSOLVED OXYGEN CONTENT, COMPRISING ACETAMINOPHEN, AND OPTIONALLY ONE OR MORE NSAIDs, AND A COMPOSITION OBTAINED THEREOF |
| PCT/EP2018/060205 WO2018193099A1 (en) | 2017-04-20 | 2018-04-20 | METHOD FOR PREPARING A COMPOSITION WITH A LOW DISSOLVED OXYGEN CONTENT, COMPRISING ACETAMINOPHEN, AND OPTIONALLY ONE OR MORE NSAIDs, AND A COMPOSITION OBTAINED THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2019011569A2 true CO2019011569A2 (es) | 2021-03-08 |
Family
ID=58645031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2019/0011569A CO2019011569A2 (es) | 2017-04-20 | 2019-10-18 | Método para preparar una composición con un bajo contenido de oxígeno disuelto, que comprende paracetamol, y opcionalmente uno o más aine, y una composición obtenida de la misma |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US11413241B2 (es) |
| EP (1) | EP3612157A1 (es) |
| JP (1) | JP6944590B2 (es) |
| KR (2) | KR20230160413A (es) |
| CN (1) | CN110719773A (es) |
| AR (1) | AR111484A1 (es) |
| AU (1) | AU2018255376B2 (es) |
| CA (1) | CA3060325A1 (es) |
| CL (1) | CL2019002985A1 (es) |
| CO (1) | CO2019011569A2 (es) |
| EC (1) | ECSP19075614A (es) |
| IL (1) | IL270035B2 (es) |
| MX (1) | MX2019012508A (es) |
| PE (1) | PE20191793A1 (es) |
| PH (1) | PH12019502385A1 (es) |
| RU (1) | RU2019137019A (es) |
| SA (1) | SA519410340B1 (es) |
| SG (1) | SG11201909726YA (es) |
| TW (1) | TW201841632A (es) |
| WO (2) | WO2018192664A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115040475A (zh) * | 2022-06-23 | 2022-09-13 | 杭州浙中医药科技有限公司 | 一种n-乙酰半胱氨酸口服溶液 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2751875B1 (fr) | 1996-08-05 | 1998-12-24 | Scr Newpharm | Nouvelles formulations liquides stables a base de paracetamol et leur mode de preparation |
| FR2809619B1 (fr) * | 2000-06-06 | 2004-09-24 | Pharmatop | Nouvelles formulations aqueuses de principes actifs sensibles a l'oxydation et leur procede d'obtention |
| US20060100578A1 (en) | 2004-09-13 | 2006-05-11 | Tandem Medical, Inc. | Medication delivery apparatus and methods for intravenous infusions |
| US20110124730A1 (en) | 2008-01-03 | 2011-05-26 | Wockhardt Research Centre | Oral pharmaceutical suspension comprising paracetamol and ibuprofen |
| BRPI0914086A2 (pt) | 2008-10-14 | 2020-01-21 | Aft Pharmaceuticals Ltd | uso de paracetamol e ibuprofeno na preparação de um medicamento para o tratamento de osteoartrite moderada ou severa ou artrite reumatoide moderada ou severa e método de tratamento de osteoartrite moderada ou severa ou artrite reumatoide moderada ou severa |
| EP2243477A1 (de) | 2009-04-22 | 2010-10-27 | Fresenius Kabi Deutschland GmbH | Paracetamol zur parenteralen Verabreichung |
| US8404748B2 (en) | 2009-08-13 | 2013-03-26 | Neogen N.V. | Storage-stable formulation of paracetamol in aqueous solution |
| PL2389923T3 (pl) | 2010-05-19 | 2013-06-28 | Uni Pharma Kleon Tsetis Pharmaceutical Laboratories S A | Trwały, gotowy do użycia iniekcyjny preparat paracetamolu |
| PL2635269T3 (pl) | 2010-11-04 | 2019-11-29 | Aft Pharmaceuticals Ltd | Kompozycja złożona |
| US9205037B2 (en) | 2011-07-20 | 2015-12-08 | Church & Dwight Co., Inc. | Single phase depilatory composition |
| ES2414557B1 (es) * | 2012-01-16 | 2014-06-10 | Novocat Farma, S.A. | Composición acuosa de paracetamol para inyección |
| BE1020614A5 (nl) | 2012-01-27 | 2014-01-07 | Hubert De Backer Nv | Injectiespuit. |
| CN106890137B (zh) | 2012-03-16 | 2020-09-25 | 坎伯兰医药品股份有限公司 | 可注射布洛芬制剂 |
| US9072661B2 (en) | 2012-03-16 | 2015-07-07 | Cumberland Pharmaceuticals Inc. | Injectable ibuprofen formulation |
| WO2016008546A1 (en) | 2014-07-18 | 2016-01-21 | Everbright Pharmaceuticals S.A.R.L. | Aqueous formulation comprising paracetamol and ibuprofen |
-
2017
- 2017-04-20 WO PCT/EP2017/059440 patent/WO2018192664A1/en active Application Filing
-
2018
- 2018-04-18 TW TW107113225A patent/TW201841632A/zh unknown
- 2018-04-20 WO PCT/EP2018/060205 patent/WO2018193099A1/en active Search and Examination
- 2018-04-20 CN CN201880035790.3A patent/CN110719773A/zh active Pending
- 2018-04-20 RU RU2019137019A patent/RU2019137019A/ru unknown
- 2018-04-20 EP EP18718164.9A patent/EP3612157A1/en active Pending
- 2018-04-20 US US16/605,711 patent/US11413241B2/en active Active
- 2018-04-20 CA CA3060325A patent/CA3060325A1/en active Pending
- 2018-04-20 AU AU2018255376A patent/AU2018255376B2/en active Active
- 2018-04-20 MX MX2019012508A patent/MX2019012508A/es unknown
- 2018-04-20 KR KR1020237039452A patent/KR20230160413A/ko not_active Application Discontinuation
- 2018-04-20 SG SG11201909726Y patent/SG11201909726YA/en unknown
- 2018-04-20 KR KR1020197032849A patent/KR102625301B1/ko active IP Right Grant
- 2018-04-20 AR ARP180101010A patent/AR111484A1/es unknown
- 2018-04-20 JP JP2020508076A patent/JP6944590B2/ja active Active
- 2018-04-20 PE PE2019002070A patent/PE20191793A1/es unknown
-
2019
- 2019-10-17 IL IL270035A patent/IL270035B2/en unknown
- 2019-10-18 CO CONC2019/0011569A patent/CO2019011569A2/es unknown
- 2019-10-18 CL CL2019002985A patent/CL2019002985A1/es unknown
- 2019-10-20 SA SA519410340A patent/SA519410340B1/ar unknown
- 2019-10-21 PH PH12019502385A patent/PH12019502385A1/en unknown
- 2019-10-21 EC ECSENADI201975614A patent/ECSP19075614A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020522564A (ja) | 2020-07-30 |
| AR111484A1 (es) | 2019-07-17 |
| PH12019502385A1 (en) | 2020-09-14 |
| CN110719773A (zh) | 2020-01-21 |
| WO2018192664A1 (en) | 2018-10-25 |
| TW201841632A (zh) | 2018-12-01 |
| AU2018255376A1 (en) | 2019-11-07 |
| SG11201909726YA (en) | 2019-11-28 |
| EP3612157A1 (en) | 2020-02-26 |
| RU2019137019A (ru) | 2021-05-20 |
| RU2019137019A3 (es) | 2021-07-05 |
| SA519410340B1 (ar) | 2022-03-13 |
| KR20230160413A (ko) | 2023-11-23 |
| IL270035B1 (en) | 2023-01-01 |
| JP6944590B2 (ja) | 2021-10-06 |
| IL270035A (es) | 2019-12-31 |
| WO2018193099A1 (en) | 2018-10-25 |
| CL2019002985A1 (es) | 2020-01-31 |
| PE20191793A1 (es) | 2019-12-24 |
| AU2018255376B2 (en) | 2023-07-06 |
| MX2019012508A (es) | 2020-02-05 |
| ECSP19075614A (es) | 2019-11-30 |
| US20210338578A1 (en) | 2021-11-04 |
| US11413241B2 (en) | 2022-08-16 |
| CA3060325A1 (en) | 2018-10-25 |
| KR20190137859A (ko) | 2019-12-11 |
| IL270035B2 (en) | 2023-05-01 |
| KR102625301B1 (ko) | 2024-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP18093651A (es) | Formulación farmacéutica líquida estable | |
| CR20180185A (es) | Métodos y composiciones para el tratamiento de estados de enfermedad asociados con respuestas inflamatorias anormales | |
| CL2017001488A1 (es) | Benzamidas sustituidas con 1,3–tiazol–2–ilo | |
| DOP2016000210A (es) | Proceso para producir una solución inyectable de noradrenalina de baja concentración, estable | |
| CL2016001076A1 (es) | (aza) piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinolosis. | |
| BR112015017251A8 (pt) | composições farmacêuticas compreendendo doadores de nitroxil, misturas e usos das referidas composições farmacêuticas | |
| PE20170470A1 (es) | Metodos y composiciones para tratar la obesidad, prevenir el aumento de peso, promover la perdidad de peso, promover el adelgazamiento o tratar o prevenir el desarrollo de la diabetes | |
| EA201790726A1 (ru) | Фармацевтическая композиция для лечения язвенного колита | |
| EA201891783A1 (ru) | Композиция для растворения аморфных дитиазинов и способ ее применения | |
| CO2019011569A2 (es) | Método para preparar una composición con un bajo contenido de oxígeno disuelto, que comprende paracetamol, y opcionalmente uno o más aine, y una composición obtenida de la misma | |
| CL2018000032A1 (es) | Método para mejorar la solubilidad acuosa de drogas insolubles o ligeramente solubles en el agua | |
| AR096887A1 (es) | Inhibidor de producción de aflatoxina y procedimiento para combatir la contaminación con aflatoxina | |
| ECSP17022124A (es) | Composición farmacéutica sólida que comprende amlodipino y losartán | |
| AR103608A1 (es) | Sales de difeniliodonio como inhibidoras de la sulfidogénesis y antimicrobianas | |
| CO2019007531A2 (es) | 3-hidroxibutirato solo o en combinación para su uso en el tratamiento de cuidados intensivos | |
| CO2020006395A2 (es) | Régimen de dosificación de edasalonexent para el tratamiento de distrofia muscular | |
| ECSP16095557A (es) | Métodos para tratar infecciones | |
| BR112017012975A2 (pt) | formulações injetáveis de paracetamol | |
| EA201792502A1 (ru) | Кабазитаксел и его применение для лечения рака | |
| BR112018071882A2 (pt) | filtro de cigarro contendo alginite | |
| Diaz | The Organization and Administration of Anesthesia Care during World War II: American vs ANZAC Experiences | |
| AR106203A1 (es) | Terapia combinada y régimen de tratamiento del hcv | |
| BR112017009326A2 (pt) | forma de dosagem e método para administração oral de um fármaco gastricamente impraticável à corrente sanguínea de um mamífero, e, kit. | |
| TH1701007010A (th) | สูตรผสมทางเภสัชกรรมสำหรับการปลดปล่อยแบบหน่วงของเซบาโคอิลไดนัลบูฟีน | |
| BR112018009102A2 (pt) | método para suprimir a redução de concentração do composto isotiazolinona |